Financings in Brief: SurVivaLink
This article was originally published in The Gray Sheet
SurVivaLink: Automated external defibrillator firm completes $11.2 mil. private placement of Series A preferred stock. Proceeds will go toward "aggressive global marketing," according to a June 17 release. Lead investors in the placement are Fidelity Ventures Limited and Fidelity Investors, L.P. Other institutional investors include CIBC Wood Gundy Ventures, The Spray Venture Fund, L.P., Wellmark, Inc., and Minnesota Management Partners I Limited. Wessels, Arnold & Henderson served as placement agent for the offering. SurVivaLink canceled plans to go public via an initial offering of 3 mil. shares last year due to poor market conditions, the firm explains ("The Gray Sheet" June 24, 1996, p. 13)...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.